“A lot was known about Huntington’s disease before we ... over the majority of the life of the affected neuron before cell death. This provides a longer time span for therapeutic applications.

Electricity has been fundamental to modern life and economic growth for more ... according to 2021 data from the Centers for Disease Control and Prevention, outpacing the state average of 8.8 ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approv ...

About a million Americans a year are expected to develop dementia by 2060, roughly double today’s toll, researchers reported Monday. That estimate is based on a new study that found a higher lifetime ...

At first, researchers believed that the number of CAG repeats only rose as the HTT gene was inherited; a child of a parent with Huntington's disease may experience the disorder earlier in life.

Scientists are unraveling the mystery of what triggers Huntington's disease, a devastating and fatal hereditary disorder that ...

A recent study published in Cell reveals that the repeated DNA sequence that leads to Huntington’s disease (HD) expands ...

People genetically susceptible to Huntington's disease often see their movement, mood, and cognition decline slowly over time. The cause is related to expansion of repeating DNA units, in which ...

The genetic mutation linked to Huntington's has long been known, but scientists haven't understood how people could have the mutation from birth, but not develop any problems until later in life.

With this new funding, Atalanta aims to advance its investigational RNAi therapies for KCNT1-related epilepsy and Huntington's disease to Phase ... led by EQT Life Sciences. This Series B will ...